Provided by Tiger Trade Technology Pte. Ltd.

Enanta Pharmaceuticals

13.47
+0.34002.59%
Post-market: 13.470.00000.00%19:30 EDT
Volume:335.25K
Turnover:4.50M
Market Cap:390.88M
PE:-5.75
High:13.70
Open:13.27
Low:13.09
Close:13.13
52wk High:17.15
52wk Low:7.05
Shares:29.02M
Float Shares:22.51M
Volume Ratio:1.57
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3416
EPS(LYR):-3.8381
ROE:-70.12%
ROA:-12.28%
PB:3.87
PE(LYR):-3.51

Loading ...

Enanta Files Appeal in Ongoing Patent Dispute With Pfizer Over Paxlovid

MT Newswires Live
·
Jun 24

Enanta Pharmaceuticals - Federal Circuit Affirms '953 Patent Claims Invalid on June 23, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 24

Enanta loses Paxlovid patent appeal as US appeals court invalidates claims

Reuters
·
Jun 24

Enanta Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 23

EU approves AbbVie’s Mavyret, discovered by Enanta, for acute hepatitis C treatment

Reuters
·
Jun 23

Enanta Pharmaceuticals’ Partner Abbvie Receives European Commission Approval of Maviret® (Glecaprevir/Pibrentasvir) for People With Acute Hepatitis C Virus

THOMSON REUTERS
·
Jun 23

Enanta Pharmaceuticals Advances RSV Drug to Phase 2/3 Trial After US FDA Meeting

MT Newswires Live
·
Jun 18

Enanta advances zelicapavir into registrational Phase 2b/3 RSV trial in high-risk adults

Reuters
·
Jun 18

Enanta Pharmaceuticals - Phase 2B Trial in Pediatric Rsv Patients to Start Q3 2026

THOMSON REUTERS
·
Jun 18

Enanta Pharmaceuticals Announces Advancement of Its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (Rsv)

THOMSON REUTERS
·
Jun 18

Enanta Pharmaceuticals - Registrational Phase 2B/3 Trial in High-Risk Adults With Rsv to Start Q4 2026; With Topline Phase 2B Data Expected in 2027

THOMSON REUTERS
·
Jun 18

Enanta Pharmaceuticals to speak at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

Enanta Pharmaceuticals (ENTA) Q2 Loss Improvement Tests Bearish Profitability Narratives

Simply Wall St.
·
May 15

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Simply Wall St.
·
May 14

Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Orchestra BioMed Holdings (OBIO)

TIPRANKS
·
May 12

Enanta Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Enanta Pharma Q2 EPS $(0.45) Beats $(0.49) Estimate, Sales $17.159M Beat $17.092M Estimate

Benzinga Earnings
·
May 12

Enanta FY26 Q2 net loss narrows to $13.1 million; revenue rises to $17.2 million

Reuters
·
May 12

BRIEF-Enanta Pharmaceuticals Q2 Revenue USD 17.159 Million Vs. IBES Estimate USD 17.1 Million

Reuters
·
May 12

Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Second Quarter Ended March 31, 2026

THOMSON REUTERS
·
May 12